Objective: Circulating tumor cells (CTCs) have been interest of subject in the past few decades in terms of prognosis and response to the therapy in several cancers and have potential as a "liquid biopsy" in the diagnosis and treatment of cancer. The aim of our study was to improve a convenient method for the strategies of CTC enrichment and detection.
Introduction
The clinical importance of circulating tumor cells (CTC) as a new target for early cancer detection, diagnosis, prognosis and prediction has been widely investigated in recent years (1) . The analysis of CTC presents the opportunity for a minimally invasive 'liquid biopsy' that provides the evaluation of disease response and targeting therapy for patients (2) . Thus, CTCs can be used for determining metastases and prognosis of cancer patients. CTCs in the peripheral blood of cancer patients are promising research area in the field of biomarker development and novel treatment for targeting in today's cancer research (3) . CTCs are only found 1 in 10 5 -10 8 numbers of leukocytes in the peripheral blood of cancer patients (4) . For this reason, highly sensitive assays with techniques to enrich and detect for CTCs are required (2) .
In general, four approaches are mainly used for the strategies of CTC enrichment that are size-based, density-based, immunomagnetic separation and microfluidic-based. For the detection of CTCs, two approaches include nucleic acid-based techniques and/or protein-based techniques (3, 4) (Table 1, Figure 1 ).
The aim of our study was to improve a convenient method for the strategies of CTC enrichment and detection. We prefered to use a density-based (ficoll) and an immunomagnetic separation (CD45 negative selection) for the enrichment and detection of CTCs. CTCs were analyzed by a flow cytometry. • Cellwash (BD Biosciences, San Jose, California)
Materials and Methods

Material
• Cytofix Fixation Buffer (CFB) (BD Biosciences, San Jose, California)
• Mouse Anti-Human CD45-APC-H7 (BD Biosciences, San Jose, California)
• Anti-EpCAM-PE (BD Biosciences, San Jose, California)
• Flow Cytometry Staining Buffer (with Fetal Bovine Serum (FBS)) (FCSB) (BD Biosciences, San Jose, California)
• Perm/wash Buffer (PWB) (BD Biosciences, San Jose, California)
• Permbuffer III (PIII) (BD Biosciences, San Jose, California)
• Mouse Anti-Human Cytokeratin 14-15-16-19-Alexa 647 (BD Biosciences, San Jose, California)
• Anti-Cytokeratin-FITC (BD Biosciences, San Jose, California)
Method
The peripheral blood samples (7.5 mL) from cancer patients and healthy volunteers were collected in EDTA-coated tubes and they were stored at room temperature.
The Strategy of CTC enrichment a. Dansity gradient separation
This step consists of the isolation of mononuclear cells by ficoll gradient centrifugation. positive selection) or contaminating blood cells (e.g., CD45; negative selection) and incubation in a magnetic field. 
Detection strategies
Protein
Immunofluorescence Flow Cytometry
Nucleic Acid
RT-PCR qPCR
**Single or Multiplex
Detection ing a 3 mL pasteur pipette in a new 50 mL conical tube. This layer contains of lymphocytes, monocytes and thrombocytes. 5. Cells are washed in 10 mL PBS and centrifuge at 300xg for 10 minutes at 20°C. 6. The supernatant is completely removed and the pellet is broken by flicking the bottom of the tube. 7. Repeat the step 5 and 6. 8. 10 mL PBS is added. 9. 10 µL cell suspension is counted with thoma chamber (Isolab).
b. Magnetic separation
This step includes the CD45 negative selection by using a magnetic separation.
1. Centrifuge at 300xg for 10 minutes at 20°C. Then, the supernatant is removed. 12. Collect unlabeled cells passing through and wash the column with 1 mL of MACs buffer twice. Collect the total effluent containing CTCs. 13. 10 µL unlabeled cell fraction is counted with a thoma chamber.
The Strategy of CTC Detection
The unlabelled cell fractions are separated as a negative control tube and a test tube. After the magnetic seperation step, transfer 50 µL unlabelled cells suspension into a negative control tube for defining a gating strategy and transfer the rest of unlabelled cell fractions into a test tube. 10. Centrifuge at 350xg for 5 minutes at 4°C and remove the supernatant.
11. Repeat the step 9 and 10.
12. Add 100 µL Permbuffer III gently while vortexing.
13. Incubate in the dark for 30 minutes at 4-8°C.
14. Repeat the step 9 and 10.
15. Add 100 µL Flow Cytometry Staining Buffer.
16. Add a fluorochrome-labeled antibody for the detection of intracellular antigens (e.g. cytokeratins).
17. Incubate in the dark for 30 minutes at 4-8°C.
18. Repeat the step 9 and 10.
19. Add 500 µL Flow Cytometry Staining Buffer and vortex it carefully.
The negative control and test tubes are analyzed by flow cytometry (The BD FACS Aria™ III Cell Sorter).
Conclusion
CTCs have been shown that they are an important tool for diagnosis, prognosis, observation of disease, the effect of the treatment and the evaluation of the recurrence in cancer patients (3). They let us to gain a better understanding about the expansion mechanism of tumor cells and shows a great potential on controlling and hindering metastasis disease (5).
As outlined in this study, we modified to improve the technique for enumerating CTCs in 7,5 mL peripheral blood samples. Our study was approved by the local human ethics committee (Ankara Ataturk Training and Research Hospital, Ankara/Turkey, 135). The patient group was composed of breast cancer patients who were newly diagnosed, untreated with identified stage while the control group consisted of healthy volunteer carrying no suspicion of cancer in this study. On the first step of our study, PBMCs were isolated from the whole blood samples by using ficoll gradient separation for patient and control groups ( Figure 2 ). Next, PBMCs were passed through with magnetic microbeads conjugated with CD45 and were eliminated from leukocytes. On the second step of our study, the retain cells were labelled with In this study, we prefered to use EpCAM-based and CK14, 15, 16, 19-based gating strategies for the detection of CTC's. The results showed that CTCs were not detected in the blood sample of a healhty volunteer (Figure 3 ), but 9 CTCs were captured with EpCAMbased gating strategy and 7 CTCs were detected with CK14, 15, 16, 19-based gating strategy in the blood sample of a breast cancer patient (Figure 4) . It is accepted that the cut off value is 5 CTCs for breast cancer (6) and CTC is negative if it is below this value or CTC is considered as a positive, if it is equal to or above this value, which might be an indication for poor prognosis.
As a result, CTCs were detectable in blood sample of cancer patients such as breast cancer, lung cancer, colorectal cancer, bladder cancer, and laryngeal cancer using with our modified convenient method for the strategies of CTC enrichment and detection.
